{"id":972,"date":"2023-09-12T09:21:49","date_gmt":"2023-09-12T07:21:49","guid":{"rendered":"http:\/\/apmonia-therapeutics.com\/?p=972"},"modified":"2023-09-12T09:39:37","modified_gmt":"2023-09-12T07:39:37","slug":"apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology","status":"publish","type":"post","link":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/","title":{"rendered":"Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology"},"content":{"rendered":"\n<p><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"702\" height=\"994\" src=\"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h18_39.png\" alt=\"\" class=\"wp-image-973\" srcset=\"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h18_39.png 702w, https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h18_39-212x300.png 212w\" sizes=\"(max-width: 702px) 100vw, 702px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"701\" height=\"986\" src=\"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h19_06.png\" alt=\"\" class=\"wp-image-974\" srcset=\"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h19_06.png 701w, https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h19_06-213x300.png 213w\" sizes=\"(max-width: 701px) 100vw, 701px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":977,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[],"class_list":["post-972","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology - Apmonia therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology - Apmonia therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Apmonia therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-12T07:21:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-12T07:39:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h39_10.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1195\" \/>\n\t<meta property=\"og:image:height\" content=\"934\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin6547\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin6547\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/\"},\"author\":{\"name\":\"admin6547\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/#\\\/schema\\\/person\\\/6b64aaf82f3c886a35dba57ea5fbe3f5\"},\"headline\":\"Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology\",\"datePublished\":\"2023-09-12T07:21:49+00:00\",\"dateModified\":\"2023-09-12T07:39:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/2023-09-12_09h39_10.png\",\"articleSection\":[\"Press Release\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/\",\"url\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/\",\"name\":\"Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology - Apmonia therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/2023-09-12_09h39_10.png\",\"datePublished\":\"2023-09-12T07:21:49+00:00\",\"dateModified\":\"2023-09-12T07:39:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/#\\\/schema\\\/person\\\/6b64aaf82f3c886a35dba57ea5fbe3f5\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/2023-09-12_09h39_10.png\",\"contentUrl\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/2023-09-12_09h39_10.png\",\"width\":1195,\"height\":934},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/2023\\\/09\\\/12\\\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/\",\"name\":\"Apmonia therapeutics\",\"description\":\"contact@apmonia-therapeutics.com\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/#\\\/schema\\\/person\\\/6b64aaf82f3c886a35dba57ea5fbe3f5\",\"name\":\"admin6547\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5383de875ee431c82c2031a4f3e2f1a19b7d0debe3754031e1ee8a4050246830?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5383de875ee431c82c2031a4f3e2f1a19b7d0debe3754031e1ee8a4050246830?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5383de875ee431c82c2031a4f3e2f1a19b7d0debe3754031e1ee8a4050246830?s=96&d=mm&r=g\",\"caption\":\"admin6547\"},\"url\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/author\\\/admin6547\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology - Apmonia therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/","og_locale":"en_US","og_type":"article","og_title":"Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology - Apmonia therapeutics","og_url":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/","og_site_name":"Apmonia therapeutics","article_published_time":"2023-09-12T07:21:49+00:00","article_modified_time":"2023-09-12T07:39:37+00:00","og_image":[{"width":1195,"height":934,"url":"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h39_10.png","type":"image\/png"}],"author":"admin6547","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin6547"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/#article","isPartOf":{"@id":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/"},"author":{"name":"admin6547","@id":"https:\/\/apmonia-therapeutics.com\/#\/schema\/person\/6b64aaf82f3c886a35dba57ea5fbe3f5"},"headline":"Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology","datePublished":"2023-09-12T07:21:49+00:00","dateModified":"2023-09-12T07:39:37+00:00","mainEntityOfPage":{"@id":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h39_10.png","articleSection":["Press Release"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/","url":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/","name":"Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology - Apmonia therapeutics","isPartOf":{"@id":"https:\/\/apmonia-therapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/#primaryimage"},"image":{"@id":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h39_10.png","datePublished":"2023-09-12T07:21:49+00:00","dateModified":"2023-09-12T07:39:37+00:00","author":{"@id":"https:\/\/apmonia-therapeutics.com\/#\/schema\/person\/6b64aaf82f3c886a35dba57ea5fbe3f5"},"breadcrumb":{"@id":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/#primaryimage","url":"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h39_10.png","contentUrl":"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2023\/09\/2023-09-12_09h39_10.png","width":1195,"height":934},{"@type":"BreadcrumbList","@id":"https:\/\/apmonia-therapeutics.com\/index.php\/2023\/09\/12\/apmonia-therapeutics-announces-a-new-licensing-agreement-with-satt-nord-to-strengthen-its-portfolio-of-innovative-peptides-for-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/apmonia-therapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology"}]},{"@type":"WebSite","@id":"https:\/\/apmonia-therapeutics.com\/#website","url":"https:\/\/apmonia-therapeutics.com\/","name":"Apmonia therapeutics","description":"contact@apmonia-therapeutics.com","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/apmonia-therapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/apmonia-therapeutics.com\/#\/schema\/person\/6b64aaf82f3c886a35dba57ea5fbe3f5","name":"admin6547","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5383de875ee431c82c2031a4f3e2f1a19b7d0debe3754031e1ee8a4050246830?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5383de875ee431c82c2031a4f3e2f1a19b7d0debe3754031e1ee8a4050246830?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5383de875ee431c82c2031a4f3e2f1a19b7d0debe3754031e1ee8a4050246830?s=96&d=mm&r=g","caption":"admin6547"},"url":"https:\/\/apmonia-therapeutics.com\/index.php\/author\/admin6547\/"}]}},"_links":{"self":[{"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/posts\/972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/comments?post=972"}],"version-history":[{"count":1,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/posts\/972\/revisions"}],"predecessor-version":[{"id":975,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/posts\/972\/revisions\/975"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/media\/977"}],"wp:attachment":[{"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/media?parent=972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/categories?post=972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/tags?post=972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}